Avoid common mistakes on your manuscript.
Correction to: Infect Dis Ther https://doi.org/10.1007/s40121-022-00734-5
Data errors have been found in the original article. These errors are highlighted here and the original article has been corrected.
The two main errors were:
-
1.
The AR-related regimen discontinuation:
-
The misclassification of one AR-related regimen discontinuation in DTG/ABC/3TC arm (from skin manifestation to renal toxicity).
-
One episode of dyslipidemia-related regimen discontinuation in DTG/ABC/3TC arm was mistakenly labeled in B/F/TAF arm.
-
There was only one episode of skin manifestation in B/F/TAF, not two episodes.
-
There is also an error in the statistical analysis for categorical variables in Table 3.
-
-
2.
The subgroup analysis of the determinant of regimen discontinuation is the determinant limited to AR or virological failure-related regimen discontinuation, instead of being limited to AR-related regimen discontinuation.
All errors are corrected below (in bold).
Before | After |
---|---|
Correction 1 1. The AR-related regimen discontinuation: The misclassification of one AR-related regimen discontinuation in DTG/ABC/3TC arm (from skin manifestation to renal toxicity) One episode of dyslipidemia-related regimen discontinuation in DTG/ABC/3TC arm was mistakenly labeled in B/F/TAF arm. There was only one episode of skin manifestation in B/F/TAF, not two episodes. There is also an error in the statistical analysis for categorical variables in Table 3. | |
In the method, under the subtitle of working definition | |
Reasons that were classified as other included pregnancy, lifestyle and diet considerations, drug–drug interactions, or provider choice. ARs were further categorized as central nervous system toxicity (dizziness, headache, insomnia, abnormal dreams, or vertigo), skin manifestations (pruritus, rash, or hypersensitivity reaction), gastrointestinal or hepatic toxicity (gastrointestinal intolerability, nausea, vomiting, jaundice, or hepatitis), or renal toxicity (declining estimated glomerular filtration rate or proteinuria) | Reasons that were classified as other included pregnancy, lifestyle and diet considerations, drug–drug interactions, or provider choice. ARs were further categorized as central nervous system toxicity (dizziness, headache, insomnia, abnormal dreams, or vertigo), skin manifestations (pruritus, rash, or hypersensitivity reaction), gastrointestinal or hepatic toxicity (gastrointestinal intolerability, nausea, vomiting, jaundice, or hepatitis), or renal toxicity (declining estimated glomerular filtration rate, electrolyte imbalance, or proteinuria) |
In the result, under the subtitle of Time to regimen discontinuation | |
The most common reason for discontinuation in both groups was ARs (61.9% [13/21] in the DTG/ABC/3TC group and 50% [2/4] in the B/F/TAF group, P = 0.877), and skin manifestations were the most common ARs in both groups (69.2% in the DTG/ABC/3TC group and 100% in the B/F/TAF group, P = 0.485). | The most common reason for discontinuation in both groups was ARs (61.9% [13/21] in the DTG/ABC/3TC group and 50% [2/4] in the B/F/TAF group, P = 0.877), and skin manifestations were the most common ARs in both groups (61.5% in the DTG/ABC/3TC group and 50% in the B/F/TAF group, P = 0.756). |
In the discussion, the 5th paragraph | |
In the present study, 9.09% of individuals in the DTG/ABC/3TC group experienced regimen discontinuation due to AR, of which skin manifestations were the most common (69.2%). | In the present study, 8.08% of individuals in the DTG/ABC/3TC group experienced regimen discontinuation due to AR, of which skin manifestations were the most common (61.5%). |
In the discussion, the 6th paragraph | |
In this retrospective cohort study, it was not possible to confirm the incidence of AR-related regimen discontinuation due to HSR (the term “HSR” was recorded in the electronic medical records for two patients in the DTG/ABC/3TC group who discontinued treatment). | In this retrospective cohort study, it was not possible to confirm the incidence of AR-related regimen discontinuation due to HSR (the term “HSR” was suspected in the electronic medical records for two patients in the DTG/ABC/3TC group who discontinued treatment). |
Correction 2 2. The subgroup analysis of the determinant of regimen discontinuation is the determinant limited to AR or virological failure-related regimen discontinuation, instead of being limited to AR-related regimen discontinuation. | |
In the abstract, under the subtitle of result | |
The main reason for discontinuation in both groups was ARs (61.9% in the DTG/ABC/3TC and 50% in the B/F/TAF, P = 0.877), of which skin manifestations were the most common in both groups (69.2% in the DTG/ABC/3TC and 100% in the B/F/TAF, P = 0.485). DTG/ABC/3TC, same-day ART prescription, and AOI were risk factors for AR-related regimen discontinuation. | The main reason for discontinuation in both groups was ARs (61.9% in the DTG/ABC/3TC and 50% in the B/F/TAF, P = 0.877), of which skin manifestations were the most common in both groups (61.5% in the DTG/ABC/3TC group and 50% in the B/F/TAF group, P = 0.756). DTG/ABC/3TC, same-day ART prescription, and AOI were risk factors for AR or virological failure-related regimen discontinuation. |
In the abstract, under the subtitle of conclusion | |
In the real world, the risk of regimen discontinuation was higher in PLWAH on coformulated DTG/ABC/3TC than in those on B/F/TAF, with no difference in viral suppression or virological failure. Given the findings concerning the effect of same-day ART prescription and AOIs on AR-related regimen discontinuation, individualized approaches to PLWAH are necessary. | In the real world, the risk of regimen discontinuation was higher in PLWAH on coformulated DTG/ABC/3TC than in those on B/F/TAF, with no difference in viral suppression or virological failure. Given the findings concerning the effect of same-day ART prescription and AOIs on AR or virological failure-related regimen discontinuation, individualized approaches to PLWAH are necessary. |
In the result, under the subtitle of Time to regimen discontinuation | |
When reasons for regimen discontinuation were limited to ARs, same-day prescription (aHR = 11.15, 95% CI: 3.03–40.98; P < 0.001) and AOI (aHR = 4.49, 95% CI: 1.23–16.37; P < 0.023) were associated with a significantly higher risk of regimen discontinuation. | When reasons for regimen discontinuation were limited to ARs or virological failure, same-day prescription (aHR = 11.15, 95% CI: 3.03–40.98; P < 0.001) and AOI (aHR = 4.49, 95% CI: 1.23–16.37; P < 0.023) were associated with a significantly higher risk of regimen discontinuation. |
In the discussion, the 8th paragraph | |
The incidence of AR-related regimen discontinuation was also associated with AOIs and same-day ART, possibly due to drug–drug interactions between non-cART regimens for AOIs and cART or toxicities attributable to AOI treatment [15, 16, 40] | The incidence of AR or virological failure-related regimen discontinuation was also associated with AOIs and same-day ART, possibly due to drug–drug interactions between non-cART regimens for AOIs and cART or toxicities attributable to AOI treatment [15, 16, 40] |
In the conclusion | |
Although the regimens do not differ in time to viral suppression or virological failure, B/F/TAF is preferred over DTG/ABC/3TC for initial therapy in PLWAH because B/F/TAF is more tolerable. Whether skin manifestations contribute to AR-related discontinuation of DTG/ABC/3TC requires further prospective investigation. Further, the strong associations of same-day ART prescription and AOIs with AR-related regimen discontinuation may indicate the need for individualized approaches to treatment-naïve PLWAH in the era of rapid ART. | Although the regimens do not differ in time to viral suppression or virological failure, B/F/TAF is preferred over DTG/ABC/3TC for initial therapy in PLWAH because B/F/TAF is more tolerable. Whether skin manifestations contribute to AR-related discontinuation of DTG/ABC/3TC requires further prospective investigation. Further, the strong associations of same-day ART prescription and AOIs with AR or virological failure-related regimen discontinuation may indicate the need for individualized approaches to treatment-naïve PLWAH in the era of rapid ART. |
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Lee, CY., Lee, CH., Tang, HJ. et al. Correction to: Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study. Infect Dis Ther 12, 863–869 (2023). https://doi.org/10.1007/s40121-023-00764-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40121-023-00764-7